title: [The case of rofecoxib(Vioxx)-what do we learn from this case].
authors.affiliation: lauri.vuorenkoski@stakes.fi
authors.forename: Lauri
authors.initials: L
authors.lastname: Vuorenkoski
mesh_terms: D004345:Drug Industry; D005387:Finland; D006801:Humans; D007400:Interprofessional Relations; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D010353:Patient Education as Topic; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007783:Lactones; D013450:Sulfones; C116926:rofecoxib